Västra Hamnen Corporate Finance has released a research update on Scandinavian ChemoTech following its report for Q2 2019. The report shows several promising developments, not least the increased focus on the veterinary market. Yet the near-term outlook makes us adjust our valuation interval somewhat downwards.
· Increased focus on veterinary market and progress towards CE mark
· Yet the near-term outlook unlikely to meet our projections
· We lower forecasts and cut valuation range to SEK 15.40 – 23.70 per share
ChemoTech released its second quarter report earlier this week. In it,